BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple Myeloma

December 1, 2016 7:51 AM EST Send to a Friend
BTIG affirms bluebird bio, Inc. (Nasdaq: BLUE) with a Buy rating and $83 price target following strong results from bb2121 ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login